RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Perihilar Cholangiocarcinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Editorial Comment: Borderline Resectability in Perihilar Cholangiocarcinoma-as Simple as ABC or 1-2-3?
Soreide Kjetil et al., Annals of surgical oncology (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867595/
- 2.
Evaluation of Extrahepatic Bile Duct Resection as a Parenchyma-Preserving Alternative in Bismuth I-II Perihilar Cholangiocarcinoma: A Comparative Single-Center Analysis.
Keshi Eriselda et al., Journal of hepato-biliary-pancreatic sciences (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42861690/
- 3.
ASO Visual Abstract: Intraoperative Para-aortic Lymph Node Sampling to Guide Surgical Decision-Making in Perihilar Cholangiocarcinoma.
Takenouchi Akira et al., Annals of surgical oncology (12 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42864566/
- 4.
Long-Term Outcomes of a Multidisciplinary Treatment Strategy Using Neoadjuvant Gemcitabine Plus S-1 Based on Anatomical Resectability Classification and Lymph Node Status in Patients with Perihilar Cholangiocarcinoma.
Kuriyama Naohisa et al., Cancers (8 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42882932/
- 5.
Impact of Repeated Endobiliary Radiofrequency Ablation on Survival in Unresectable Perihilar Cholangiocarcinoma.
Lee Yoonchan et al., Endoscopy (2 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42826731/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Perihilar Cholangiocarcinoma
Perihilar cholangiocarcinoma is a rare cancer of the bile ducts that forms where the main ducts leave the liver. It can block bile flow and cause jaundice, itching and weight loss. Treatment may include surgery to remove the affected duct and part of the liver, liver transplant in selected people, chemotherapy and procedures to drain the bile ducts.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Perihilar Cholangiocarcinoma?
Perihilar cholangiocarcinoma is a rare cancer of the bile ducts that forms where the main ducts leave the liver. It can block bile flow and cause jaundice, itching and weight loss. Treatment may include surgery to remove the affected duct and part of the liver, liver transplant in selected people, chemotherapy and procedures to drain the bile ducts.
How many clinical trials are available for Perihilar Cholangiocarcinoma?
RareWays currently indexes 60 clinical trials for Perihilar Cholangiocarcinoma, of which 12 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Perihilar Cholangiocarcinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Perihilar Cholangiocarcinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.